24: Population-Based Analysis of Outcomes for Patients with Brain Metastases from Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitor Alone Or Combined with Radiotherapy.

MLA

Kong, Timothy, et al. “24: Population-Based Analysis of Outcomes for Patients with Brain Metastases from Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitor Alone Or Combined with Radiotherapy.” Radiotherapy & Oncology, vol. 163, Oct. 2021, pp. S13–14. EBSCOhost, https://doi.org/10.1016/S0167-8140(21)08902-7.

APA

Kong, T., Nichol, A., Ho, C., Benny, A., Chooback, N., Fraser, I., Gondara, L., & Lefresne, S. (2021). 24: Population-Based Analysis of Outcomes for Patients with Brain Metastases from Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitor Alone Or Combined with Radiotherapy. Radiotherapy & Oncology, 163, S13–S14. https://doi.org/10.1016/S0167-8140(21)08902-7

Chicago

Kong, Timothy, Alan Nichol, Cheryl Ho, Alexander Benny, Negar Chooback, Ian Fraser, Lovedeep Gondara, and Shilo Lefresne. 2021. “24: Population-Based Analysis of Outcomes for Patients with Brain Metastases from Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitor Alone Or Combined with Radiotherapy.” Radiotherapy & Oncology 163 (October): S13–14. doi:10.1016/S0167-8140(21)08902-7.